Home › Esophageal Adenocarcinoma › Virginia
Esophageal Adenocarcinoma clinical trials in Virginia
13 studies for Esophageal Adenocarcinoma are looking for participants at sites in Virginia.
Cities in Virginia
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT05677490Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Inova Schar Cancer Institute, Fairfax
- Virginia Cancer Specialists, PC, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06324357A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Oncology and Hematology Associates of Southwest Virginia, Inc. - Salem, Salem
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07221149Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Virginia Cancer Specialists, PC, Arlington
- Virginia Oncology Associates, Chesapeake
- Virginia Cancer Specialists, PC, Fairfax
- and 7 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07392892A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Blacksburg
- Research Site, Fairfax
- Research Site, Fort Belvoir
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT06657144A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT07284186A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT05954312From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.